☰

QUELL

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of QUELL's published strategy and is not endorsed by, or produced in cooperation with, QUELL. Company website

Strategic priorities

QUELL operates across 4 stated priorities, with the most concrete near-term plan anchored on phenotypic stability.

Ensuring 100% stable, persistent Tregs through proprietary Phenotype-Lock™ technology with constitutive Foxp3 expression to prevent phenotypic plasticity and regulatory conversion.

Engineering CAR-Tregs with exquisite tissue trafficking capabilities using HLA-A2 targeting for liver transplant tolerance and tissue-specific homing receptors.

Building world-leading clinical and commercial supply through multi-site GMP capacity at Stevenage CGT Catapult and eXmoor Pharma Bristol facilities.

Challenges we see

  • Operations Manufacturing

    Autologous Manufacturing Variability

    Quell's autologous CAR-Treg production requires isolating rare CD4+ T-cell subsets from patient apheresis material, with starting material quality varying significantly between a 65-year-old liver transplant patient and healthy donors.

    Inconsistent yields and high batch failure rates during 14-36 day G-Rex bioreactor expansion phases directly impact Cost of Goods Sold and delay patient treatment.

  • Digital Manufacturing

    Bioreactor Black Box Monitoring

    Current expansion process relies on periodic manual sampling to check cell counts and viability, providing only snapshots of cell health while increasing contamination risk with each intervention.

    Process deviations may not be detected until final QC, at which point the entire batch investment is unrecoverable and Phenotype-Lock™ stability cannot be validated in real time.

  • Operations Regulatory

    Chain of Identity/Custody Fragmentation

    Distributed manufacturing model requires secure, temperature-controlled transport of cryopreserved materials between clinic, White City central lab, and manufacturing sites at Stevenage or Bristol with multiple hand-off points.

    Manual, hand-off-heavy COI/COC processes across multiple sites are ripe for human error, creating compliance risks for FDA/EMA regulatory submissions.

  • Digital Integration

    Joining records across systems

    Analysis reveals fragmentation between corporate IT (NetSuite, React/jQuery) and manufacturing OT systems, with no unified MES or LIMS integrating bioreactor data from Stevenage with R&D omics datasets at White City.

    Digital silos block the cross-site analytics required to optimize manufacturing yields and correlate phenotypic stability data across patient populations and clinical cohorts.

  • Compliance Regulatory

    Paper-Based GMP Batch Records

    Regulatory ecosystem signals indicate continued reliance on manual, paper-intensive batch records which conflict with the audit-ready digital infrastructure required for $2B AstraZeneca partnership transparency.

    Digitalized, audit-ready data infrastructure is a prerequisite for partnership data sharing, tech transfer to US facilities, and expedited regulatory review timelines.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Real-Time Phenotype Monitoring

    Scientists cannot monitor Foxp3 expression and phenotypic stability during the 14-36 day expansion cycle, discovering "phenotype flip" risks only at final QC when the batch is already lost.

    Implement IoT-enabled soft sensors and digital twin modeling to predict epigenetic methylation changes during expansion, enabling early intervention or run termination before resources are wasted.

  2. Unified Manufacturing Data Platform

    Critical process data is trapped in silos—bioreactor readings at Stevenage, omics data at White City, QC results in disconnected systems—preventing cross-cohort optimization and regulatory reporting.

    Deploy an ontology-driven data lakehouse that unifies SCADA, LIMS, and research datasets into a single source of truth, enabling automated OPV reporting and AI-powered yield optimization.

  3. Digital Chain of Identity

    Manual COI/COC tracking across apheresis sites, central labs, and manufacturing facilities creates high risk of identity errors and thermal excursions that could compromise patient safety and batch integrity.

    Implement blockchain-enabled chain of identity tracking providing tamper-proof digital ledger from patient bedside to bioreactor and back, ensuring absolute regulatory compliance and real-time visibility.

  4. Paperless GMP Batch Records

    Paper-based batch records and manual transcription violate ALCOA+ principles, creating FDA audit risk and preventing efficient data sharing with AstraZeneca for tech transfer to their $300M Rockville facility.

    Implement Laboratory Execution System (LES) with automated data capture from instruments, real-time compliance verification, and digital batch record generation ready for regulatory submission.

  5. Digital Tech Transfer Capability

    Quell must transfer manufacturing processes to AstraZeneca's US facility with 100% fidelity, but lacks digital infrastructure for creating portable process blueprints and validating remote operator training.

    Build digital twin of Stevenage process with VR-based operator training modules and secure cloud-native environment for sharing GMP batch records and CMC data with AstraZeneca manufacturing sites.

What we'd propose

  • Digital Lab

    Real-Time Bioreactor Intelligence Platform

    IoT-enabled monitoring system integrating soft sensors with biological simulation models to provide real-time Foxp3 expression estimates and phenotypic stability predictions during CAR-Treg expansion.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Unified Manufacturing Data Lakehouse

    Ontology-driven data platform unifying SCADA, LIMS, and omics datasets across Stevenage, Bristol, and White City sites into a single source of truth with automated regulatory reporting.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Digital Chain of Identity & Custody System

    Blockchain-enabled track-and-trace platform providing tamper-proof digital ledger for patient materials from apheresis through manufacturing to infusion with real-time temperature monitoring.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Laboratory Execution System Implementation

    Comprehensive LES deployment replacing paper-based batch records with automated data capture, real-time compliance verification, and digital documentation for GMP manufacturing.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Digital Tech Transfer Platform

    Cloud-native environment for creating portable manufacturing blueprints, VR-based operator training, and secure CMC data sharing to enable process replication at AstraZeneca's Rockville facility.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what QUELL's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Process Data Integration 35 → 85
Fragmented IT/OT systems with NetSuite ERP disconnected from manufacturing SCADA; no unified MES/LIMS spanning sites
Real-Time Analytics 25 → 80
Omics data analysis localized in bioinformatics teams with significant lag to operational decisions; no live stability monitoring
Digital Compliance 40 → 90
Paper-based batch records and manual COI/COC tracking conflict with ALCOA+ principles; limited audit-ready infrastructure
Manufacturing Intelligence 30 → 85
Black box bioreactor expansion with periodic sampling only; no predictive modeling for yield optimization
Cross-Site Connectivity 35 → 80
Data silos between White City R&D, Stevenage manufacturing, and Bristol operations prevent cross-cohort analytics
Partner Data Exchange 20 → 85
No secure digital infrastructure for CMC data sharing with AstraZeneca; tech transfer relies on manual documentation

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with QUELL, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].